Research programme: glucocorticoid receptor II antagonists - Corcept Therapeutics

Drug Profile

Research programme: glucocorticoid receptor II antagonists - Corcept Therapeutics

Alternative Names: CORT 112716; CORT 113083; CORT 118335; CORT 122928; CORT 125281

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Corcept Therapeutics
  • Class
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alcoholism; Alzheimer's disease; Amyotrophic lateral sclerosis; Cancer; Memory disorders; Metabolic disorders; Muscular dystrophies; Non-alcoholic fatty liver disease; Obesity; Post-traumatic stress disorders; Prostate cancer; Psychiatric disorders

Most Recent Events

  • 30 Jan 2017 Preclinical trials in Prostate cancer in USA (PO) before January 2017
  • 30 Jan 2017 Corcept Therapeutics plans a phase I trial of CORT 125281 for Prostate cancer
  • 30 Jan 2017 Corcept Therapeutics plans a phase I trial of CORT 118335 for Non-alcoholic fatty liver disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top